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Abstract 
Background: Nationally adult immunization rates continue to fall below the current 
benchmark goals. It is estimated adult vaccinations range from 20 to 60 percent, 
depending on the vaccine. There are different vaccine schedules for those of average-risk 
compared to those with high-risk conditions. Providers are being encouraged to explore 
their administration of vaccines as preventable, communicable diseases continue to be 
seen. Objectives: In a primary care clinic, a gap analysis was conducted to: 1.) 
Determine adult immunization rates, 2.) Compare vaccine administration rates of the 
Tdap, PCV13, PPSV23, and influenza vaccines between average and high-risk adults, 3.) 
Determine if specific chronic diseases correlate with increased or decreased vaccination 
rates. Methods: A retrospective chart review was conducted on a random sample of 120 
patients in an urban, primary care clinic. The chart review was utilized to assess vaccine 
administration for those 50 to 64 years of age, who were high-risk status based on 
specific diseases, compared to average-risk adults, ages 65 to 80 years of age. Results: 
Comparing groups, average-risk patients had a higher rate of immunizations for three of 
the four vaccines (influenza, PCV13 and PPSV23), with a statistically significant 
difference favoring the average-risk group for PCV13 and influenza. Only the Tdap 
vaccine had higher frequency in the high-risk group but was not statistically significant. 
Conclusions: Immunization rates were low for both populations which concurs with 
national data. Possible explanations include difficulties with documentation in the EMR 
to the lack of emphasis placed on vaccines by patients and providers. Clearly, attention 
must be placed on adult immunizations and their role in preventive care.   
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A Gap Analysis on Vaccine Administration in Average and High-Risk Adults 
Introduction 
Population health has been substantially improved through the advent of vaccines for 
preventable diseases. Unfortunately, there is a gap in patients either accepting vaccines and/or 
providers recommending their administration. According to a recent report adult immunization 
rates continue to remain low, it is estimated adult vaccinations range from 20 to 60 percent, 
depending on the vaccine (Huston, 2014). The reasons for this are multifactorial and include 
patients’ fear of their safety to providers not finding the time to discuss the recommended 
vaccines. The purpose of this gap analysis is to identify the current percentage of adults in a 
primary care practice who are vaccinated. Further, the analysis will compare rates of 
administration between average and high risk adults.  
Background and Significance 
Vaccinations play a key role in the prevention of disease. Healthy People 2020 indicates 
immunizations prevent 14 million cases of communicable disease (United States Department of 
Health and Human Services, 2017a). In addition, immunizations are said to reduce direct 
healthcare costs by $9.9 billion dollars, and $33.4 billion in indirect healthcare cost (United 
States Department of Health and Human Services, 2017a). 
Immunization guidelines have been published by the United States Advisory Committee 
on Immunization Practices (ACIP) and other acting committees since 1984 (Orenstein, Pickering 
& Walton, 2014). These resources are used to provide clinicians on what, when, and how often 
specific vaccines are needed. The adult vaccine guideline recommendations are reevaluated 
yearly by the ACIP, the American Academy of Family Physicians (AAFP), the American 
College of Physicians (ACP) and the American College of Nurse Midwives (ACNM; Orenstein 
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et al., 2014).  Currently, there are seventeen different preventable diseases listed on the adult 
immunization schedule that can be reduced through receiving proper vaccinations (United States 
Department of Health and Human Services, 2015a).  The vaccinations for these diseases are 
recommended during adulthood based on age, prior/current immunization status, and attributing 
risk factors. The ACIP also identifies when vaccinations should be given for those with high-risk 
health conditions. For example, patients who are diagnosed with chronic obstructive pulmonary 
disorder (COPD) should receive their first pneumococcal vaccine between the ages of 19 to 64 
years of age (Centers for Disease Control and Prevention, 2015c; Centers for Disease Control 
and Prevention, 2015d). 
Healthy People 2020 has established adult vaccination benchmark goals, which vary 
depending on the type of vaccine and health status of a patient. Overall, no vaccine has reached 
the established, current benchmark goals (United States Department of Health and Human 
Services, 2015b). Reasons for this can be aligned to patient factors (fear, cost, beliefs, lack of 
understanding) to attention given by providers on vaccine administration (Johnson, Lipzynski, & 
Nichol, 2008; Ahmed et al., 2014). It is prudent for all clinicians to include vaccinations in 
preventive care. The first step for any primary care practice is to recognize their own benchmark 
in adult vaccinations, to develop a quality improvement process. 
Relevant Literature 
Search Description  
A review of the literature was conducted by a search of the worldwide web and using the 
online resources available through the University of Kentucky Medical Library. The search 
conducted utilized CINAHL, Google, Google Scholar and PubMed. Words used during the 
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search consisted of: chronic disease, adult, immunizations, prevention, vaccinations, vaccines, 
influenza, pneumococcal, PPSV23, PCV13, Tdap, providers, and barriers.  
Background on Vaccinations 
 Immunotherapy via vaccinations was initiated in the 18th century, with cowpox being the 
first developed (The College of Physicians of Philadelphia, 2017). The number of vaccines has 
grown exponentially since then, reducing the devastating effects of many communicable 
diseases, such as measles, diphtheria, and pertussis. They are meticulously tested by the Food 
and Drug Administration (FDA) with emphasis on effectiveness and safety (FDA, 2016a). Their 
use has made the sheer recognition of the diseases they cover difficult to identify. It is through 
childhood administration that our initial immunotherapy is initiated, and it is through repeat 
vaccinations in adulthood that further prevent the diseases. Only the influenza; tetanus, 
diphtheria and pertussis (Tdap); pneumococcal conjugate (PCV13); and pneumococcal 
polysaccharide (PPSV23) recommended adult vaccinations will be discussed, as they are the 
focus of this project (See Table 1).  
Influenza vaccine. 
 Influenza is one of the most common communicable diseases, with recognized mortality 
especially in infants, children and older adults (Centers for Disease Control and Prevention, 
2014). The vaccine is reassessed and formulated yearly to cover the recent strains and mutations 
based on prior seasons. Administration of the vaccine for flu prevention starts at the age of six 
months and continues throughout life (Grohskopf et al., 2016). This vaccine is the only one 
requiring yearly administration. Its overall efficacy rate is between 10 to 76% (Centers for 
Disease Control and Prevention, 2015b). Unless there is a prior severe reaction to the vaccine 
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there are no other contraindications to its administration (Centers for Disease Control and 
Prevention, 2016a; Table 1).  
Tetanus, diphtheria and pertussis (Tdap) vaccine. 
 The initial vaccine series, known as diphtheria, tetanus and pertussis (DTap) is started in 
infancy and completed by age seven (Centers for Disease Control and Prevention, 2017c). The 
initial dose of Tdap is administered around 11 years of age with a second dose at 19 years of age 
(Centers for Disease Control and Prevention, 2017b; Centers for Disease Control and Prevention, 
2017c). The vaccine’s antigenic effect wanes overtime requiring periodic boosters. The vaccine 
has three components, two of these must be administered every ten years (tetanus and diphtheria) 
and the other (pertussis) requires one dose in adulthood (Centers for Disease Control and 
Prevention, 2017b). The exception to this recommendation is that women should get vaccinated 
with Tdap in every pregnancy (Centers for Disease Control and Prevention, 2015f). 
Contraindications for vaccine administration involve severe reaction to a vaccine component or 
encephalopathy within seven days of a prior pertussis vaccine (Centers for Disease Control and 
Prevention, 2017a; Table 1). 
Pneumococcal vaccines. 
 The pneumococcal vaccine has two formulations recommended by the ACIP; the 13-
valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal 
polysaccharide vaccine (PPSV23; Tomczyk et al., 2014). PCV13 immunizes against thirteen 
strains of pneumonia, while PPSV23 protects against twenty-three (FDA, 2016b; FDA, 2014; 
Table 1). The initial series is of the PCV13 is given in infancy and completed by 15 months of 
age (Centers for Disease Control and Prevention, 2017c). The Centers for Disease Control and 
Prevention (CDC) recommends adults, who are considered average risk, ages 65 years of age and 
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older, receive one dose of the PCV13 followed by the PPSV23, in six to twelve months (CDC, 
2015d; Kobayashi et al., 2015).  
There are differences in the vaccine administration schedule when high-risk conditions 
are present. The PPSV23 should be administered to those individuals with chronic lung disease, 
chronic heart disease, diabetes, cochlear implants, cerebrospinal fluid leaks and 
immunosuppression, beginning at 19 years of age and older, with one dose re-administer at age 
65, unless the patient has been vaccinated within the last five years (CDC, 2017b). Additionally, 
cigarette smokers are considered in those who should be vaccinated earlier with PPSV23 (CDC, 
2015c).  
The disparity in recommendation within the CDC is who should receive the PCV13, prior 
to age 65, in adulthood (CDC, 2012; CDC, 2015d; CDC, 2015c; CDC, 2017b). The issue centers 
on what is defined as a high-risk condition. There is some thought that only those with 
immunosuppression, cochlear implants and cerebrospinal fluid leaks should receive the PCV13 
prior to age 65, however some guidelines include diabetes mellitus, chronic lung and heart 
disease (CDC, 2012; CDC, 2015c; CDC, 2015d; CDC, 2017b). In 2018, the ACIP will initiate a 
full review of these vaccines to provide clarity for healthcare providers (Crawford, 2014a).  
 Contraindication for PCV13 and PPSV23 administration includes an anaphylactic 
reaction to a vaccine component or pregnancy (CDC, 2017a; CDC, 2015c). The PCV13 vaccine 
has an additional contraindication, which is if the patient has had a prior reaction to a diphtheria 
vaccine (CDC, 2017a; Table 1). Overall, the vaccine is considered very safe but the schedule for 
administration is confusing. 
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Current State of Vaccinations 
Healthy People 2020 establishes benchmark goals to increase the number of vaccinations 
administered for preventable disease (United States Department of Health and Human Services, 
2017a). The benchmark goals are focused on the pneumococcal vaccines, the influenza vaccine, 
and the zoster vaccine (United States Department of Health and Human Services, 2017b). 
However, this project did not focus on the zoster vaccine due to documentation issues and 
complications with communication of vaccine administration, as it is administered at 
pharmacies. Further compromising a full understanding of adult vaccination rates is the lack of 
monitoring by the CDC, along with children and adult data tends to be merged together.  
 Per the United States Department of Health and Human Services (2017b), a 70% 
administration rate is the yearly goal for adults, over the age of 18, to receive the influenza 
vaccine. Recent statistics for the 2014-2015 influenza season revealed 47% of individuals six 
months and older received the vaccine (Centers for Disease Control and Prevention, 2016c). The 
CDC (2015a) reported Kentucky’s influenza administration rates was 48.3%, for the same 
season. The overall burden of influenza in this season, across all age groups, was forty-million 
flu-like illnesses, and nearly one-million hospitalizations (CDC, 2015b). In that same year, over 
60% of flu-related hospitalizations, were among people 65 years and older (CDC, 2015b). 
The administration goal for the pneumococcal vaccine is 90% for those of average risk 
and 60% for high-risk adults (United States Department of Health and Human Services, 2017b). 
Based upon 2014 data, only 61.3% of adults, 65 years and older, had received one of the 
pneumococcal vaccines (United States Department of Health and Human Services, 2015b). In 
this same year, Kentucky’s pneumococcal immunization rate was reported at 69.3% (Trust for 
America’s Health, 2016). In regards to the high-risk population the national current state was at 
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16.6% (United States Department of Health and Human Services, 2017b). There was no 
breakdown of administration for the PCV13 and PPSV23, separately.  
Vaccine preventable diseases, not specifically listed in Healthy People 2020, also have 
low percentages of adults who received other vaccines, specifically, Tdap. After extensive 
research, no national or state goals could be found for this vaccine but it is just as necessary as 
the others. Although there is no established goal, a target should be what is needed to obtain herd 
immunity. An article by Willingham and Helft (2014) reported threshold immunization rates 
needed to be at 85% for the diphtheria and 95% for pertussis to attain the herd effect. 
The National Health Interview Survey (NHIS), performed January through December 
2014, reported of those surveyed, 19 years and older, 20.1% had received the Tdap vaccine 
(Williams et al., 2016). In 2012, there were over 48,000 cases of pertussis reported (CDC, 
2015e), and in 2015, Northern Kentucky Independent District Health Department (2017) 
reported 317 cases in their area alone. Though this highly contagious disease can be managed in 
adults, it can be deadly for infants and children.  
Patient and Provider Barriers 
 Barriers to vaccine administration play a key role in low vaccine rates. These are from 
both the provider and consumer perspective. A study conducted by Johnson et al. (2008) found 
that 56 to 60% of providers knew the correct vaccine guidelines. Additionally, they found 79 to 
85% of patients (out of 2,002 surveyed) would be willing to get any immunizations 
recommended; however, this was not mentioned in their office visit (Johnson et al., 2008). 
Furthermore, Johnson et al. (2008) reported that over 50% of providers surveyed admitted to not 
following the CDC recommendations, with no explanation provided. 
9 
 
 Another contributing factor to the deficient vaccine rates is the expense associated with 
vaccines. Ahmed et al. (2014) found the main reason providers do not carry, stock, or discuss 
vaccines is due to the lack of reimbursement. Additionally, time to discuss vaccines during an 
appointment was also identified (National Center for Immunizations & Respiratory Diseases, 
2013). Further findings were, the providers did not want to deal with vaccines because of the 
associated costs, high rates of patient refusal, and the risk of expiration before administration 
(Ahmed et al., 2014).  Yet, per the CDC, all health insurance marketplace plans and many 
private insurers cover the most common vaccines, without a copay or co-insurance (CDC, 
2016b). Medicare also has coverage for the influenza and pneumococcal vaccines (Centers for 
Medicare and Medicaid Coverage, n.d.). 
 Patient barriers are a major factor in relation to low immunization rates. Burns, Kimmel, 
Wolfe and Zimmerman (2007) reported multifactorial reasons why patients were not immunized. 
They described patient barriers as confusion of what vaccines were needed, transportation issues 
to the clinic and inconvenient clinic hours. Fear of getting the disease from the vaccine 
(specifically influenza) was also an identified barrier in the adult population (Hall et al., 2003). 
Additionally, concern about the patient’s ability to afford the vaccine was reported by 39% 
(n=71) of those surveyed (Hall et al., 2003).  
Although, pediatric vaccinations are tracked with established goals, there is no consistent 
data, outside of convenience surveys, for adults.  These surveys provide limited data on who 
receives vaccines, and if there is any discrepancy between the high and average risk groups. 
There is no national database for adult vaccination rates, it behooves clinics to evaluate their own 
practice, recognizing that the goal should be 100% of those eligible should be vaccinated. Thus, 
the aim of this project was to evaluate the adult immunization status of specified high-risk 
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subjects (COPD, asthma, diabetes mellitus, heart failure and specific autoimmune diseases) 
versus those who are at average risk for developing these diseases.  
Objectives 
The purpose of this study was to perform a gap analysis on vaccine administration in 
average and high-risk adults, between 50 to 80 years of age. The age span was used to 
encompass vaccine recommendations for individuals who are high risk and are eligible to receive 
specific vaccines before the age of 50. The site selected for this gap analysis was an urban, 
primary care clinic in Lexington, Kentucky. The time span selected was May 1st, 2016 through 
July 31st, 2016 to capture the influenza vaccine administration from the prior season.  There were 
three objectives for this gap analysis: 
Objective 1: Determine immunization status (administered, non-administered, refused) 
Objective 2: Compare vaccine administration rates of the Tdap, PCV13, PPSV23, and  
          influenza vaccines between average and high-risk adults. 
Objective 3:  Determine if specific co-morbidities correlate with increased or 
                            decreased vaccination rates. 
Methods 
Study Design 
A retrospective chart review was performed through the utilization of the University of 
Kentucky’s Center for Clinical and Translational Sciences. A retrospective review of 120 
randomly selected electronic health records, of patients meeting the study criteria, were 
evaluated. The review included 60 individuals, 50 to 64 years old, with COPD, asthma, diabetes 
mellitus, heart failure or an autoimmune disorder; and 60 individuals, 65 to 80 years of age, with 
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no high-risk diagnosis. Immunization status for the Tdap, PCV13, PPSV23, and influenza 
vaccines was evaluated.   
All subjects were seen at the Polk Dalton Clinic between May 1st, 2016 through July 31st, 
2016. This time range was selected to assess a time when the influenza vaccine was not actively 
being administered, so a full season (2015-2016) season of administration could be assessed. The 
records were obtained through an administrator with the University of Kentucky Center for 
Clinical and Translational Sciences— Biomedical Informatics group. This information was then 
provided and stored in the University of Kentucky REDCap database. The information obtained 
was de-identified of all 18 personal health identifiers. 
Study Population 
The setting of this study was the Polk Dalton Clinic, specifically their primary care 
services. This clinic was developed to serve the Northside and urban community of Lexington. It 
strives to provide care to the entire family, from infancy to elderly. 
One population of interest for this project were patients 50 to 64 years of age who had 
one or more of the following diagnoses: diabetes mellitus, chronic obstructive pulmonary 
disease, asthma, heart failure and specified autoimmune diseases.  This was determined using 
appropriate ICD-10 and ICD-9 codes (Appendix). The other group were patients between 65 to 
80 years of age with no high-risk diagnoses. The age difference between the groups is present to 
assess if the high-risk population is being vaccinated earlier for the pneumococcal vaccines 
(which is what should be occurring). There were no exclusions or exemptions made for race, 
ethnicity or sex/gender of any subjects for either population. 
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Statistical Analysis 
 Data analysis occurred using SPSS 22 and Microsoft Excel. Analysis of data was carried 
out by frequencies, Fischer’s exact, Mann-Whitney U, and chi-squared tests. Comparisons were 
made among the two designated groups, along with demographical and individual 
immunizations. Chi-squared tests were utilized to show if a gap was present, and if the gap was 
significant. An alpha level of .05 was used to determine statistical significance.  
Results 
The entire sample of both average and high-risk patients had no statistically significant 
differences for gender and race (Table 3). The sample consisted of 62.5% females with African- 
Americans being the predominant race (55%).  The average age in the high-risk group was 56 
and in the average-risk group it was 70 years of age (Table 4). The most common high-risk 
condition was found to be diabetes mellitus (n=50), see figure one for a complete analysis of the 
various conditions. It should be noted that 18% (n=11) of the high-risk group had more than one 
co-morbidity.  
Objective 1 
 The immunization status for the entire group was evaluated. In total, the influenza 
vaccine had the highest rate at 70%, followed by PCV13 at 48%, Tdap at 34% and PPSV23 at 
18% (Table 5).  
Objective 2 
 Immunization rates between the high and average-risk groups was evaluated. The 
influenza vaccine was administered to 80% (n=48) in the average risk group and in 60% (n=36) 
of the high-risk group. The Tdap vaccine was received by 32% (n=19) of the average risk and 
37% (n=22) of the high-risk group. When assessing the pneumococcal vaccines, the PCV13 was 
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administered to 67% (n=40) of the average risk and 30 % (n=18) of the high-risk. Lastly, for 
PPSV23, 20% (n=12) of the average risk population received the vaccine, while only 15% (n=9) 
had received the vaccine in the high-risk group. The completion of the pneumococcal vaccines 
was also evaluated and noted to be completed in 18% (n=11) of the average risk and only 5% 
(n=3) of the high-risk patients (Table 6). There was a significant statistical difference between 
administration rates of influenza, PCV13 and the completion of the pneumococcal series, 
favoring the average risk group (Table 6). (See Figure 2 for comparison graph.)  
Objective 3 
 Differences between the chronic diseases and administration of vaccines was evaluated 
with percentages and chi-squared testing. Due to the low numbers of patients with asthma, heart 
disease, and the absence of anyone with an immunocompromised disease, only COPD and 
diabetes were used for comparison. Additionally, some individuals had both COPD and diabetes 
mellitus so there was also analysis done on those with combined co-morbidities. Data revealed 
that percentages favor having both co-morbidities for influenza, PCV13 and PPSV23 
administration (Table 7). The Tdap vaccine was administered to those with diabetes alone, more 
than having COPD or both diseases. When comparing, using chi-squared testing, there was no 
statistical significance between any of these groups with vaccine administration (Table 7). 
Discussion 
 There is increasing emphasis being placed on preventative care which should decrease 
morbidity and mortality, as well as healthcare costs. Part of the preventative care package must 
be to maximize vaccination rates within all served populations. Unfortunately, adult vaccination 
rates for prevention of communicable diseases continues to be an issue. Providers must begin 
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with a baseline of their own practice before implementing changes designed to improve vaccine 
administration.  
 In the clinic used for this project the influenza vaccine reached the national goal of 70% 
(Table 8). This is not surprising given its national attention. There are billboards throughout the 
city, providers automatically order it at the same time each year, and there is extensive media 
coverage. The media not only addresses the importance of getting the vaccine but puts out 
influenza alerts, again emphasizing the importance of being vaccinated. This vaccine is not 
driven by the provider alone as patients actively seek it out, unlike any other. Further, being a 
yearly vaccine there is no confusion on its timing of administration.   
The Tdap vaccine does not have a national goal, however, the rate of immunization 
within the clinic was 34%, which was higher than the current national rate (20.1%; Williams et 
al., 2016). Considering the recent outbreak of pertussis, 20% nor 34% is an acceptable vaccine 
rate seeing how devastating pertussis is on infants and children (Crawford, 2014b). Part of the 
issue surrounding this vaccine is the misconception by the public that a tetanus vaccine is only 
needed for an injury (Johnson et al., 2008). Secondly, the Tdap vaccine has only been associated 
with childhood and its administration is a relatively new recommendation for adults (Barclay & 
Vega, 2007).  Prior to 2005, only a tetanus and diphtheria booster was recommended by the 
ACIP, this changed when pertussis was recognized as a reemerging disease (Barclay & Vega, 
2007). Administration of the Tdap will improve when healthcare providers, as well as the public, 
are made aware of pertussis outbreaks and the importance of being vaccinated in adulthood.  
The pneumococcal vaccines, for the average-risk population have a national goal of 90% 
(United States Department of Health and Human Services, 2017b). In the clinic studied rates 
were 67% for PCV13 and 20% for PPSV23. In their high-risk population, only 30% were 
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immunized with the PCV13 and 15% for PPSV23, which contrasts with the national goal of 70% 
for both. It is difficult to understand the full reasons behind these immunization rates. Much like 
the Tdap the reasoning may lie with provider and public knowledge regarding the current 
recommendations.  
 The above statistics identify a need to focus on vaccine administration within the clinic. 
Sadly, the high-risk population has lower rates for nearly all the vaccines when compared to the 
average-risk group. Comparing the diabetics to the COPD patients no statistical differences were 
noted in their vaccination rates. Interestingly, COPD patients were not immunized at higher rates 
for any of the vaccines when compared to those in the average-risk group, which is of concern as 
to why respiratory centered vaccines are not regularly considered by healthcare providers. 
However, there of course may be variables not captured that may explain the low rates of 
vaccine administration in this group. 
Chronic care patients who typically have more clinic visits throughout the year should be 
well immunized. Yet it is not unusual to see inadequate administration within high-risk groups. 
In a study conducted by Nowalk, Zimmerman, Cleary and Bruehlman (2005) chronic care 
patients though seen more frequently had many missed opportunities for vaccine administration. 
One explanation was the amount of time providers spent on the patient’s chronic care issues. 
Additionally, patient refusal and the ever-changing vaccine schedule adds to these missed 
opportunities.  
There are other complicating factors that impact patients and providers. Unlike, 
vaccinations in childhood there is no pressure on adults to receive vaccines, unless they work in 
the healthcare industry. Childhood vaccinations have long been the focus of preventive care 
visits that are scheduled and well-funded. Current childhood vaccination rates remain at 90% 
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throughout the United States (Schuchat, Singleton, Whitney & Zhou, 2014). In all 50 states, 
there are laws stating their requirements and children are required to present immunization 
certificates for school entry (Buttenheim, Clymer, Davis-Hayes & Wang, 2014).  
Vaccine guidelines present many difficult challenges for providers. For example, there is 
not one universal source with clear recommendations, the ACIP releases confusing and extensive 
reports, and changes are made without notification.  It is also difficult for providers and patients 
to be current on insurance coverage for vaccines with patients being quick to ask about coverage 
before agreeing to administration. 
 Observation of the overall data reveals that neither group were consistently vaccinated at 
the recommended rates. It seems by far the highest rate of administration, for both groups, is the 
influenza vaccine. This vaccine was closest to the national benchmark goal than any other 
vaccine assessed for this project. All vaccines pose room for improvement with vaccination 
rates. Issues are present which create further question and barriers to why immunization rates 
may be low. Providers must make adult vaccinations as much of a priority as childhood, to 
increase administration. 
Implications 
 The information from this project was to provide baseline information to identify if a 
problem existed with vaccine administration for the specified populations. What this gap analysis 
did provide is evidence that these vaccines need more focus. Additionally, education, potentially 
further study, and a quality improvement project may be necessary to increase immunization 
administration for both average and high-risk patients.  
  Several ideas might be considered to improve vaccination rates in this setting. Education 
for providers and patients would be a starting point. Providers could have a lunch-in-learn 
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session on adult vaccine administration, this would allow them to review the current 
recommendations and discuss any questions or concerns. Additionally, a creation of a quick 
reference pocket guide could have basic vaccine criteria for who and when someone is or is not 
eligible, for all staff and providers. In regards to patient education, the posting of signs 
throughout the waiting area, hallways and rooms about all adult vaccines would be a way to 
draw their attention.  
The patient’s immunization status should be part of the rooming process by the medical 
assistant, just as the medications are now currently reviewed. Furthermore, to ensure this is 
taking place, the creation of a hard stop in the electronic medical record (EMR) could be 
established to address all vaccinations. A study was recently conducted at The Iowa Clinic and 
the implementation of a hard stop increased immunization rates by 21% (Landi, 2017).  Intrinsic 
within this hard stop would be the ability to document patient refusal. This would ensure every 
patient’s immunization status is a priority during any visit.  
Another idea would be to establish a clinic policy that all adults receive an immunization 
record, just like children. This certificate would show them what has been administered and what 
is needed. Additionally, these certificates could state when their next vaccine is needed. This also 
gives the patient some accountability in ensuring their immunizations are current.  
 Pharmacies providing vaccines have created an additional barrier in knowledge about 
vaccine administration. The clinic could work towards contacting all area pharmacies and talk 
with them about how they can open communication. An idea for an immunization administration 
notification provided from a pharmacy could be through fax or mail.  
 On a national level, there is no regulations for adult vaccines. The ACIP needs to be as 
clear and forthcoming with adult recommendations as those for children.  Policies are needed to 
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advance adult immunizations to the rates at which we see in childhood. Nurses need to be 
involved at the state level to develop lifetime vaccine registries and work towards making them 
nationally accessible. State registries have worked well for tracking childhood vaccines and 
should be easily carried over to adults.  
Limitations 
 As with any project, especially one trying to establish baseline data, limitations presented 
themselves when carrying out this gap analysis. The quality of data was impeded because of the 
limitations of the EMR. There is not a user-friendly method of making a notation if a vaccine has 
been refused which anecdotally is often the case.   
 The level of visit could not be extracted for the visit, to see whether vaccines were missed 
at an episodic versus an annual health appointment. This would have been richer for the clinic to 
understand as far as noting a potential difference. In addition, it would have been interesting to 
understand the number of missed opportunities for vaccine administration.  
 In observing the data, the PCV13 and PPSV23 vaccines were collected separately for 
analysis but also together to see if the series was completed. There was a statistically significant 
difference for the two populations on completion of the series, however there may not be a true 
difference because of not knowing patient eligibility for both vaccines and the gap analysis did 
not capture the required wait period between the two. It is unknown what patients could have 
been in-between the immunization wait period.   
 Diversity, outside of African-Americans and Caucasians was limited in this project due to 
the low volume of other ethnicities. Immunization rates cannot be generalized for all adults. 
Furthermore, the project findings cannot be generalized for any other population due to its 
specificity for the clinic.   
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Conclusion 
 Immunization rates are low for both average and high-risk populations in this clinic. 
Further information is needed to understand vaccine issues and work flow to improve 
administration of adult immunizations. In providing care to both average and high-risk 
individuals it is imperative to provide preventive care to all adults. Providers may get 
overwhelmed with a patient’s chronic health care needs but preventive medicine is crucial to 
avert other diseases. These vaccines are what keep people healthy and prevent outbreaks of 
disease. Now that we know what the vaccine rates are, it is necessary for further action to be 
taken, to address the situation.  
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Table 1: Background, Specifics and Contraindications of Vaccines 
  Specifications Absolute Contraindications What It Prevents 
Influenza 
Recommended for all individuals 
without contraindications starting at 6 
months of age and older. (Grohskopf 
et al., 2016) 
Previous severe reaction to any influenza 
vaccine (angioedema, respiratory distress, 
emesis or the need to use epinephrine)- for 
any combination of the vaccine. For the 
live-attenuated vaccine, anyone who is 
immunosuppressed, caregivers or those in 
close contact with someone who is 
immunocompromised or pregnant women.  
(Grohskopf et al., 2016) 
Specific strains of Influenza A and B- the 
vaccine and strains change yearly to adjust 
for identified strains and mutations from 
the prior season.  
(Grohskopf et al., 2016) 
Tdap 
Recommended for individuals 11 
years and older. Also, may be 
administered to under vaccinated 
children 7 to 10 years of age. (CDC, 
2011) 
Anaphylactic reaction to a previous dose or 
vaccine component. Encephalopathy no 
attributable to another disease within 7 days 
of administration of a prior pertussis 
vaccine. (CDC, 2017a) 
Tetanus, Diphtheria, and Pertussis (a.k.a. 
"whooping cough")  
(CDC, 2011) 
PCV13 
(Pneumococcal 
Conjugate Vaccine 
or Prevnar) 
Infants and children less than 2 years 
of age, adults 65 years and older, and 
those 2 to 64 years of age with specific 
medical conditions (diabetes, chronic 
heart/lung or kidney disease, 
compromised immune systems, 
cochlear implants or cerebrospinal 
fluid leaks). (CDC, 2015d; CDC, 
2015c)  
Anaphylactic reaction to a previous PCV7 
or 13 vaccine or component, also to any 
diphtheria toxoid. (CDC, 2017a)  
Pregnancy (CDC, 2015d) 
The adult PCV13 protects against 
Streptococcus pneumoniae serotypes: 1, 3, 
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A. 19F 
and 23F. (FDA, 2016) 
PPSV23 
(Pneumococcal 
Polysaccharide 
Vaccine or 
Pneumovax) 
Adults 65 years and older, 19 through 
64 years of age- who are cigarette 
smokers, and those 2 through 64 years 
of age with specific medical conditions 
(diabetes, chronic heart/lung or kidney 
disease, compromised immune 
systems, cochlear implants or 
cerebrospinal fluid leaks). (CDC, 
2015d; CDC, 2015c)   
Anaphylactic reaction to a previous PPSV23 
vaccine or component. (CDC, 2017a)   
Pregnancy (CDC, 2015d) 
Protects against 23 serotypes of 
pneumococcal disease: 1, 2, 3, 4, 5, 6B, 
7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 23F, 33F).  
(FDA, 2014)  
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Table 2: Goals and Current State of Vaccines 
  Goal Current National State (%) Current KY State (%) 
Influenza 70% 47.0% 48.3% 
Tdap No data found 20.1% No data found 
Pneumococcal (65 years and older; average 
risk) 90% 61.3% 69.3% 
Pneumococcal (18-64 years; high risk) 60% 16.6%  data found 
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Table 3: Demographical characteristics of the project sample by group (n=120) 
 Total sample 
(n=120) 
High-risk 
(n=60) 
Average-risk 
(n=60) 
p 
Sex 
   Male 
   Female 
 
45 (37.5%) 
75 (62.5%) 
 
27 (45%) 
33 (55%) 
 
18 (30%) 
42 (70%) 
.09 
Race 
   Caucasian 
   African American 
   Asian 
 
53 (44%) 
66 (55%) 
1 (1%) 
 
28 (47%) 
32 (53%) 
0 (0%) 
 
25 (42%) 
34 (57%) 
1 (1%) 
.54 
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Table 4: Age Groupings of Patients  
 
AGE_GROUPING 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Age_50_55 22 18.3 18.3 18.3
Age_56_60 20 16.7 16.7 35.0
Age_61_65 18 15.0 15.0 50.0
Age_66_70 36 30.0 30.0 80.0
Age_71_75 10 8.3 8.3 88.3
Age_76_80 14 11.7 11.7 100.0
Total 120 100.0 100.0  
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Table 5: Total Population Vaccination Status 
Vaccines Vaccinated Non-Vaccinated 
Influenza 84 (70%) 36 (30%) 
Tdap 41 (34%) 79 (66%) 
PCV13 58 (48%) 62 (52%) 
PPSV23 21 (18%) 99 (82%) 
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Table 6: Vaccination rates by group 
 High risk 
(n=60) 
% vaccinated 
Average risk 
(n=60) 
% vaccinated 
p-value 
Influenza 60% 80% .017 
Tdap 37% 32% .564 
PCV13 30% 67% <.001 
PPSV23 15% 20% .471 
Completion of 
pneumococcal series 
5% 18% .023 
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Table 7: Vaccine Administration for COPD and/or Diabetes Mellitus Patients  
 
COPD Only Diabetes Only COPD and Diabetes p-value 
Influenza (n=2) 22% (n=26) 63% (n=6) 67% 0.07 
Tdap (n=2) 22% (n=17) 41% (n=3) 33% 0.54 
PCV13 (n= 3) 33% (n=10) 24% (n=4) 44% 0.46 
PPSV23 (n=1) 11% (n=6) 15% (n=2) 22% 0.79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Table 8: National Goals Compared to Clinic Rates 
   
National Goal 
 
Clinic Rate Total  
(n =120) 
Influenza 70% 70% 
Tdap No data found 34% 
Pneumococcal (65 years and older; 
average risk) 
PCV13 
PPSV23
90% 
 
 
 
 
67% 
20% 
Pneumococcal (19 to 64 years of age; high-
risk) 
PCV13 
PPSV23
70% 
 
 
 
 
 
30% 
15% 
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Figure 1: Chronic Diseases of High-Risk Individuals 
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Figure 2: High-Risk Compared to Average-Risk, Vaccination Rates 
 
 
 
 
 
 
 
 
 
60%
37%
30%
15%
5%
80%
32%
67%
20% 18%
INFLUENZA TDAP PCV13 PPSV23 COMPLETION OF 
PNEUMOCOCCAL 
SERIES
High‐Risk Compared to Average‐Risk 
Vaccinated
High risk (n=60) % vaccinated Average risk (n=60) % vaccinated
37 
 
Appendix  
ICD Codes Used for Analysis 
ICD-10 codes: 
‐  Diabetes Mellitus (Type I and II) 
Code Numbers: E10.9, E10.21, E10.22, E11.21, E11.22, E11.41, E11.42, 
    E 11.69, E11.8 and E11.9 
‐ Chronic Obstructive Pulmonary Disease 
Code Numbers: J44.0, J44.1 and J44.9 
‐ Asthma 
Code Numbers: J45.20, J45.21, J45.22, J45.30, J45.31, J45.32, J45.40,  
                          J45.41, J45.42, J45.50, J45.51, J45.52, J45.901, J45.902, 
                          J45.909 
‐ Heart Failure 
Code Numbers: I50.20, I50.21, I50.23, I50.30, I50.31, I50.32, I50.33, 
    I50.40, I50.41, I50.42, I50.43, I50.9 
‐ Autoimmune Disorders 
 Rheumatoid Arthritis  
Code Numbers: M05.9, M06.80, M06.9, M08.00, M08.29 
 Systemic Lupus Erythematosus 
Code Numbers: M32.10, M32.9 
 Multiple Sclerosis 
Code Number: G35 
 Myasthenia gravis 
Code Numbers: G70.00, G70.01 
 Autoimmune thyroiditis 
Code Number: E06.3 
 
The ICD-9 Codes: 
‐ Diabetes Mellitus (Type I and Type II) 
Code numbers: 250, 250.0, 249.0, 250.01, 250.2, 250.3 
‐ Chronic Obstructive Pulmonary Disease 
Code Numbers: 490, 491, 491.2, 491.21, 492, 496 
‐ Asthma 
Code Numbers: 493, 493.2, 493.21, 493.22 
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(Appendix Continued) 
‐ Heart Failure 
Code Numbers: 428.0, 428.1, 428.2, 428.21, 428.22, 428.23, 428.3, 428.31, 
428.32, 428.33, 428.4, 428.41, 428.42, 428.43, 428.9 
  - Autoimmune Disorders 
 Rheumatoid Arthritis: 714.0 
 Systemic Lupus Erythematous: 710.0  
 Multiple Sclerosis: 340.0 
 Myasthenia Graves: 358.0, 358.00, 358.01 
 Autoimmune Thyroiditis: 245.2 
 
 
 
 
 
 
 
